Hikma maintains its 2014 interim dividend, but pays a special..!

DividendMax Ltd.

Hikma maintains its 2014 interim dividend, but pays a special..!

Group Highlights

Group  revenue increased by 16% to $738 million, driven by the very strong performance of our Injectables business in the first half

Group adjusted operating margin rose to 33.2%, up from 29.6%, reflecting a higher Injectables margin

Profit attributable to shareholders increased by 132% to $169 million. On an adjusted basis, profit attributable to shareholders rose 44% to $176 million

Basic EPS increased 130% to 85.4 cents per share

Net cash flow from operating activities increased by $64 million to $200 million

Completed the acquisition of assets of Bedford Laboratories ("Bedford") in July 2014 and agreed to acquire substantially all of the assets of the Ben Venue manufacturing site, significantly enhancing the long term strength of our global Injectables business

Continued to build our global product portfolio through new product introductions across all countries and markets - launched 49 products and received 140 product approvals

Interim dividend of 7.0 cents per share, in line with the first half of 2013

Declared a special dividend of 4.0 cents per share, reflecting the exceptionally strong market opportunities captured by our US businesses in the first half of 2014

Companies mentioned